Executive SummaryUnder the influence of Leon Rosenberg, Bristol-Myers Squibb's research department was one of the industry most active early-stage deal makers. Now, Bristol has a new head of research, former Pfizer head of discovery research, Peter Ringrose, who is already talking about reducing the number of early-stage and platform deals to focus instead on deals that will produce INDs within two years of signing the collaboration.
You may also be interested in...
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 4)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this fourth installment of a 10-part series, the experts address so-called back rooms used by manufacturers during an inspection.
Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.